Clinical Trials
28 trialsFeasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
University of California, Irvine
PNOC020
University of Florida
TPT CED rHGG
Columbia University
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
ASP8374 + Cemiplimab in Recurrent Glioma
Dana-Farber Cancer Institute
CBT-I in PBT
Virginia Commonwealth University
AI-assisted Diagnosis of Malignant Brain Tumors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
University of California, San Francisco
EC-AIM Brain
Tufts Medical Center
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
IDeATIon
Assistance Publique - Hôpitaux de Paris
Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas
Northwell Health
GlucoCEST MRI in Oncology
University College, London
Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory
Virginia Commonwealth University
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
Northwestern University
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
University of Pittsburgh
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melphalan With BBBD in Treating Patients With Brain Malignancies
OHSU Knight Cancer Institute
Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma
Case Comprehensive Cancer Center
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
Duke University
alloCTL
Jonsson Comprehensive Cancer Center
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Duke University
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center